YOCHAI BIRNBAUM to Cardiovascular Agents
This is a "connection" page, showing publications YOCHAI BIRNBAUM has written about Cardiovascular Agents.
Connection Strength
2.571
-
When Is It Appropriate to Publish a Meta-Analysis in Cardiovascular Drugs and Therapy? Cardiovasc Drugs Ther. 2023 06; 37(3):599-601.
Score: 0.746
-
Introduction and Vision. Cardiovasc Drugs Ther. 2020 02; 34(1):1-2.
Score: 0.603
-
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovasc Drugs Ther. 2018 02; 32(1):65-72.
Score: 0.525
-
Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am J Physiol Heart Circ Physiol. 2008 Dec; 295(6):H2436-46.
Score: 0.276
-
Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: clinical evidence and possible underlying mechanisms. Am Heart J. 2007 Aug; 154(2):391-402.
Score: 0.254
-
Aleglitazar, a Balanced Dual PPARa and -? Agonist, Protects the Heart Against Ischemia-Reperfusion Injury. Cardiovasc Drugs Ther. 2016 Apr; 30(2):129-41.
Score: 0.116
-
The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol. 2004 Oct 06; 44(7):1343-53.
Score: 0.052